TNF and neoplasm: Moreover, catumaxomab binds to CD3 on T cells, triggering their activation and proliferation, causing tumor-killing molecules such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), perforin, and granzyme B to be released [38, 39].